Characteristics of the included studies, ordered by number of patients
| Study | Design | POLE seq | MSI | MMR IHC | TP53 seq | p53 IHC | Patients (n) | Type of EC | Patient N | Stage I–II n (%) | Endometrioid n (%) | Multiple-classifier n (%) | MMRd-p53abn n (%) | POLEmut-p53abn n (%) | POLE-MMRd n (%) | Triple positive n (%) |
| León-Castillo, 202016 23 | Multi | + | – | + | ± | + | 3518 | All types | 3518 | NA | NA | 137 (3.9) | 64 (1.8) | 31 (0.9) | 30 (0.9) | 12 (0.3) |
| Stelloo, 2016*5 | Multi | + | + | – | ± | + | 861 | High-intermediate risk | 861 | 861 (100.0) | 861 (100.0) | 27 (3.1) | 13 (1.5) | 7 (0.8) | 6 (0.7) | 1 (0.1) |
| Kandoth, 2013*1 | Multi | + | + | – | + | – | 530 | High risk | 530 | NA | NA | 52 (9.8) | 23 (4.3) | 13 (2.5) | 9 (1.7) | 7 (1.3) |
| Kommoss, 2018*6 | Single | + | – | + | – | + | 452 | All types | 452 | 391 (86.5) | 397 (87.8) | 8 (1.8) | 1 (0.2) | 2 (0.4) | 5 (1.1) | 0 (0) |
| Talhouk, 2017*4 | Single | + | – | + | + | + | 319 | All types | 319 | NA | 215 (67.4) | 16 (5) | 11 (3.4) | 4 (1.3) | 0 (0) | 1 (0.3) |
| Britton, 201924 | Single | + | – | + | – | + | 257 | All EC <50 y.o. | 257 | NA | 225 (87.5) | 10 (3.9) | 8 (3.1) | 0 (0) | 2 (0.8) | 0 (0) |
| Talhouk, 20153 | Single | + | – | + | + | + | 143 | All types | 143 | NA | 119 (83.2) | 12 (8.4) | 9 (6.3) | 3 (2.1) | 0 (0) | 0 (0) |
| Victoor, 202125 | Single | + | ± | + | – | + | 120 | All types | 120 | 95 (79.2) | 84 (70.0) | 4 (3.3) | 0 (0) | 1 (0.8) | 0 (0) | 3 (2.5) |
| Stelloo, 20152 | Multi | + | + | – | ± | + | 116 | High risk | 116 | 63 (54.3) | 86 (74.1) | 3 (2.6) | 1 (0.9) | 0 (0) | 2 (1.7) | 0 (0) |
| Timmerman, 202026 | Single | + | ± | + | – | + | 108 | All types | 108 | 84 (77.8) | 83 (76.9) | 4 (3.7) | 0 (0) | 1 (0.9) | 3 (2.8) | 0 (0) |
| Joehlin-Price, 202127 | Single | + | – | + | – | + | 95 | G3 endometrioid | 95 | 61 (64.2) | 95 (100.0) | 6 (6.3) | 1 (1.1) | 1 (1.1) | 3 (3.2) | 1 (1.1) |
| Kim, 202028 | Single | + | – | + | – | – | 52 | Clear cell | 52 | 35 (67.3) | 0 | 2 (3.8) | 2 (3.8) | 0 (0) | 0 (0) | 0 (0) |
| Knez, 2021†29 | Single | + | – | + | – | + | 45 | All types | 45 | 34 (75.6) | 41 (91.1) | 6 (13.3) | 2 (4.4) | 4 (8.9) | 0 (0) | 0 (0) |
| Kobayashi, 202130 | Single | + | + | + | + | + | 36 | High risk | 36 | NA | 19 (52.8) | 5 (13.9) | 4 (11.1) | 1 (2.8) | 0 (0) | 0 (0) |
| Zhang, 202131 | Single | + | – | + | – | + | 21 | Undifferentiated or dedifferentiated | 21 | 13 (61.9) | 0 | 3 (14.3) | 0 (0) | 1 (4.8) | 2 (9.5) | 0 (0) |
| Current study | Single | + | + | + | + | + | 422 | All types | 422 | 292 (69.2) | 370 (87.7) | 48 (11.4) | 28 (6.6) | 15 (3.6) | 2 (0.5) | 3 (0.7) |
The most frequent multiple-classifier class per study is highlighted in green.
*Patients included in the study by León-Castillo et al.16
†Prospective study; all the remaining studies were retrospective.
EC, endometrial cancer; IHC, immunohistochemistry; MMR, mismatch repair; MMRd, mismatch repair deficient; MSI, microsatellite instability; multi, multicenter; NA, not available; p53abn, p53 abnormal; POLEmut, POLE mutated; seq, sequencing; single, single center, triple positive.